Patents Assigned to BioStratum, Inc.
  • Patent number: 7214799
    Abstract: The invention provides non-oxidative methods for the large scale manufacture of pyridoxamine (I) (4-aminomethyl-3-hydroxy-5-hydroxymethyl-2-methylpyridine): and salts thereof. The invention also provides intermediate compounds for the synthesis of pyridoxamine, as well as compositions and methods for the treatment and/or prevention of conditions associated with the formation of post-Amadori advanced glycation end-products.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: May 8, 2007
    Assignee: BioStratum, Inc.
    Inventors: Raja Khalifah, Roland Keilitz, Christoph Koellner, Thorsten Degenhardt, Stephen Robert Brand
  • Patent number: 7105291
    Abstract: The present invention provides for compositions and methods for detecting susceptibility for basement membrane disease, in particular Congenital nephrotic syndromes of the Finnish type. The present invention provides for nucleic acids and protein for use in methods and compositions for the diagnosis of disease and identification of small molecule therapeutics for treatment of such disease, in particular of proteinuria associated with kidney disease.
    Type: Grant
    Filed: January 12, 2001
    Date of Patent: September 12, 2006
    Assignee: Biostratum, Inc.
    Inventors: Karl Tryggvason, Marjo Kestila, Ulla Lenkkeri, Minna Mannikko
  • Patent number: 6955924
    Abstract: The instant invention provides for the identification, diagnosis, monitoring, and treatment of invasive cells using the laminin 5 gamma-2 chain protein or nucleic acid sequence, or antibodies thereto.
    Type: Grant
    Filed: January 8, 2001
    Date of Patent: October 18, 2005
    Assignee: BioStratum, Inc.
    Inventors: Karl Tryggvason, Pekka Kallunki, Charles Pyke
  • Publication number: 20040224304
    Abstract: The present invention provides methods of identifying candidate compounds for the treatment of type I diabetes by identifying those test compounds that inhibit an apoCIII-induced increase in intracellular calcium concentration in pancreatic &bgr; cells. The present invention further provides methods for treating patients with type I diabetes by administering to the patient an amount effective of an inhibitor of apoCIII to reduce apoCIII-induced increase in intracellular calcium concentration in pancreatic &bgr; cells.
    Type: Application
    Filed: April 29, 2004
    Publication date: November 11, 2004
    Applicant: BioStratum, Inc.
    Inventor: Per-Olof Berggren
  • Publication number: 20040122061
    Abstract: The present invention provides compounds, pharmaceutical compositions, and methods for treating or inhibiting development of AGE- and/or ALE-associated complications in subjects in need thereof.
    Type: Application
    Filed: August 29, 2003
    Publication date: June 24, 2004
    Applicant: BioStratum, Inc.
    Inventor: Raja Khalifah
  • Patent number: 6703363
    Abstract: The present invention provides recombinant laminin 5, methods for making recombinant laminin 5, cells that express recombinant laminin 5, and methods for using the recombinant laminin 5 to accelerate wound healing, and to promote cell attachment and migration.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: March 9, 2004
    Assignee: BioStratum, Inc.
    Inventor: Ariel Boutaud
  • Patent number: 6689090
    Abstract: The instant invention provides for apparatus and methods for the efficient administration of pharmaceuticals to target cells, tissues and/or organs, for a variety of functional uses.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: February 10, 2004
    Assignee: Biostratum, Inc.
    Inventors: Karl Tryggvason, Olavi Lukkarinen, Pirkko Heikkilä, Tarja Parpala
  • Patent number: 6638907
    Abstract: The present invention provides substantially purified laminin 8, methods for making recombinant laminin 8, cells that express recombinant laminin 8, and methods for using the recombinant laminin 8 to accelerate the healing of injuries to vascular tissue and tissue of mesenchymal origin, and to promote cell attachment and migration.
    Type: Grant
    Filed: April 28, 2000
    Date of Patent: October 28, 2003
    Assignee: BioStratum, Inc.
    Inventors: Jarrko Kortesmaa, Karl Tryggvason
  • Patent number: 6576418
    Abstract: The present invention relates to a method for isolating and identifying the nucleotide sequence of the human gene for the type IV collagen &agr;5(IV) chain. The present invention is directed to the determination of the nucleotide sequence of the gene for the &agr;5(IV) collagen chain in individuals by any method known to the art, e.g. cloning from genomic DNA libraries or amplifying gene regions with the polymerase chain reaction (PCR) and studying their physical properties or nucleotide sequences. In addition, the invention is directed to the use of the nucleotide sequences of the &agr;5(IV) gene to amplify or identify the nucleotide sequences of the &agr;5(IV) gene.
    Type: Grant
    Filed: August 7, 1996
    Date of Patent: June 10, 2003
    Assignee: BioStratum, Inc.
    Inventors: Karl Tryggvason, Sirkka L. Hostikka, Jing Zhou